NCT05844228View on ClinicalTrials.gov

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

April 21, 2025

Conditions
Renal Impairment
Interventions
DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33016

Floridian Clinical Research, Miami Lakes

92377

Inland Empire Clinical Trials, Rialto

All Listed Sponsors
lead

Vir Biotechnology, Inc.

INDUSTRY

NCT05844228 - A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 | Biotech Hunter | Biotech Hunter